

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

28th May, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Sub: Press Release and Analyst Presentation on Q4FY26 and FY26 Results

Dear Sir(s)/ Madam,

With reference to relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the press release and analyst presentation on Q4FY26 and FY26 earnings and business updates and the same will be uploaded on the website of the Company.

Kindly take a note of the same.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

Press Release

Alkem reports record high EBITDA, strong revenue growth in Q4 & FY26

Mumbai, May 28, 2026: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the fourth quarter ended March 31, 2026. The Board of Directors took record of these results at its meeting held in Mumbai today.

FY26 Key Financial Metrics



Q4FY26 Key Financial Metrics



Commenting on the results, Dr. Vikas Gupta, CEO of Alkem, said, “We are pleased to report that Alkem has recorded its highest ever EBITDA in FY26, reaffirming the strength of our growth strategy, execution and operational rigour. Our top-line growth was broad-based with both domestic branded generics and international business delivering strong growth. An improving business mix, operating leverage and continued cost discipline drove meaningful margin expansion in FY26. Our financial performance in Q4 was also marked by strong revenue and EBITDA growth as well as a significant increase of 40.7% in our profit before tax and exceptional item. We enter FY27 on a firm foundation and expect healthy growth across businesses supported by increasing contribution from chronic therapies and a differentiated launch pipeline for international markets.”

Q4 FY26 Key Financial Highlights

- Total Revenue from Operations was ₹36,033 million, with YoY growth of 14.6%.
 - India sales were ₹23,245 million, YoY growth of 8.8%.
 - International sales were ₹12,223 million, with YoY growth of 25.4%.
- EBITDA was ₹5,174 million, resulting in an EBITDA margin of 14.4% vs. 12.4% in Q4 FY25. EBITDA grew by 32.2% YoY.
- R&D expenses for Q4 FY26 were ₹2,293 million, or 6.4% of total revenue from operations, vs. ₹1,585 million in Q4 FY25 at 5.0% of total revenue from operations.
- Profit before tax (before exceptional item) was ₹5,578 million, YoY growth of 40.7%.

- Exceptional items for the quarter include ₹602.7 million incremental liability towards gratuity and leave encashment for past service cost following finalisation of Central Rules under the Labour Codes, and ₹747 million impairment of real estate investments.
- Net Profit (after Non-Controlling interest) was ₹2,365 million, YoY de-growth of 22.7%.

FY26 Key Financial Highlights

- Total Revenue from Operations was ₹147,123 million, with YoY growth of 13.5%.
 - India sales were ₹98,514 million, YoY growth of 9.7%.
 - International sales were ₹46,810 million, with YoY growth of 22.5%.
- EBITDA was ₹30,052 million, resulting in an EBITDA margin of 20.4% vs. 19.4% in FY25. EBITDA grew by 19.6% YoY.
- R&D expenses for FY26 were ₹6,173 million, or 4.2% of total revenue from operations, vs. ₹5,620 million in FY25 at 4.3% of total revenue from operations.
- Profit before tax (after exceptional item) was ₹28,709 million, YoY growth of 13.6%.
- Exceptional items for the year include:
 - ₹1,130.6 million liability towards gratuity and leave encashment for past service cost following finalisation of Central Rules under the Labour Codes.
 - ₹747 million provision for impairment of real estate investments.
 - Partly offset by an exceptional gain of ₹142.9 million from reversal of impairment on sale of the Indore facility.
- Net Profit (after Non-Controlling interest) was ₹23,018 million, YoY growth of 6.3%.

Operational Highlights

Q4 FY26 Domestic Business Key Highlights

- The contribution of domestic sales to total sales was 65.5% vs. 68.7% in Q4 FY25.
- According to IQVIA (SSA) data, for Q4 FY26:
 - The Company registered a growth of 11.1% YoY vs Indian Pharmaceutical Market (IPM), which grew by 10.1%, 100 bps outperformance.
 - Acute segment reported growth of 10.0% vs IPM which grew by 7.7%, 230 bps outperformance.
 - Chronic segment reported growth of 16.1% vs. IPM which grew by 13.6%, 250 bps outperformance.
 - We have outperformed IPM in six key focused therapies: Gastro-intestinal grew by ~1.8X, VMN ~1.6X, Pain ~1.7X, Anti-Diabetic ~1.4X, Respiratory ~1.6X and Derma ~2.0X.

FY26 Domestic Business Key Highlights

- The contribution of domestic sales to total sales was 67.8% vs. 70.2% in FY25.
- According to IQVIA (SSA) data, for FY26:
 - The Company registered a growth of 9.2% YoY vs Indian Pharmaceutical Market (IPM), which grew by 9.0%, 20 bps outperformance.
 - Acute segment reported growth of 8.5% vs IPM which grew by 6.8%, 170 bps outperformance.

- Chronic segment reported growth of 12.6% vs. IPM which grew by 12.5%, 10 bps outperformance.
- We have outperformed IPM in seven key focused therapies: Anti-infectives grew by ~1.1X, Gastro-intestinal ~1.5X, VMN ~2.0X, Pain ~1.6X, Anti-Diabetic ~1.2X, Respiratory ~1.4X and Derma ~1.8X.

Q4FY26 International Business Key Highlights

- US sales were ₹7,681 million, YoY growth of 26.2%.
- US business sales contributed 21.7% to total sales in Q4 FY26 vs. 19.6% in Q4 FY25.
- Non-US sales were ₹4,543 million, YoY growth of 24.1%.
- Non-US business sales contributed 12.8% to total sales in Q4 FY26 vs. 11.8% in Q4 FY25.
- During Q4 FY26, for the US market, the Company filed 05 ANDAs and received 04 ANDAs approvals.

FY26 International Business Key Highlights

- US sales were ₹29,845 million, YoY growth of 20.3%.
- US business sales contributed 20.5% to total sales in FY26 vs. 19.4% in FY25.
- Non-US sales were ₹16,964 million, YoY growth of 27.4%.
- Non-US business sales contributed 11.7% to total sales in FY26 vs. 10.5% in FY25.
- As of March 31, 2026, the Company had filed 192 ANDAs, 02 NDAs and 01 BLA with the USFDA. It has received approvals for 167 ANDAs (including 19 tentative approvals) and 02 NDAs. The Company launched 11 products during FY26.

Facility Regulatory Status

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Apr-26	Form 483 received with 7 Observations; Audit response under submission.
Taloja R&D (India)	Bioequivalence Centre	Apr-26	EIR Awaited - No observation received.
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Sep-25	EIR Awaited - No observation received.

About Alkem: Alkem Laboratories Ltd. is the sixth - largest pharmaceutical company in the Indian market, with a legacy spanning over 50 years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 18 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring Healthier Lives” is at the core of the organization’s values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit www.alkemlabs.com and follow us on [LinkedIn](#), [Instagram](#), and [Facebook](#).

Contact

Investors:

Purvi Shah – Head of Investor Relations
+91 84337 00890
purvi.shah@alkem.com
+91-22-3982 9999 Ext: 9447

Media:

Isha Trivedi
+91 98925 90003
alkemcorpcomm@alkem.com
+91-22-3982 9999 Ext:9672



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Invite for Q4FY26 & FY26 Conference Call at 4.30 pm IST, May 28, 2026

Mumbai, May 20, 2026: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Thursday, May 28, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q4 and FY26 financial results. The call will follow the announcement of the Company's Q4 and FY26 financial results on Thursday, May 28, 2026.

Alkem Laboratories Ltd. will be represented on the call by:

Mr. Sandeep Singh - MD
Dr. Vikas Gupta – CEO, Alkem Laboratories
Mr. Nitin Agrawal – CFO

Motilal Oswal Securities Ltd will host the call.

Details of the conference call are as follows

Time	4:30 pm IST (GMT + 5:30) on Thursday, May 28, 2026.
-------------	---

Dial in Details

India	+91 22 6280 1149 / +91 22 7115 8050
--------------	-------------------------------------

International Toll-Free

USA	1 866 746 2133	UK	0 808 101 1573
Singapore	800 101 2045	Hong Kong	800 964 448

Express Join with Diamond Pass

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=0446059&linkSecurityString=3bc64f32c>

You are requested to dial in 10 minutes ahead of the scheduled start time.

Purvi Shah / Isha Trivedi

Investor Relations / Media Alkem
Laboratories Ltd.
Mobile: +91 84337 00890 / 98925 90003
Tel.: +91 22 3982 9999 Ext: 9447
E-mail: purvi.shah@alkem.com/
isha.trivedi@alkem.com

Tushar Manudhane

Institutional Research Analyst - Healthcare Motilal
Oswal Securities Ltd.
Tel.: +91 22 6129 1536 / +91 82911 38039
E-mail: Tushar.Manudhane@motilaloswal.com

Alkem Laboratories Ltd.
Q4 & FY26 Results Presentation
28th May 2026



Safe Harbor Statement



This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

CONTENTS



Company's Financial Performance



Business Updates – Q4 & FY26



Company overview and journey so far

Q4 FY26 Performance at Glance



Total Revenue from Operations

₹36,033 Mn



+14.6% YoY Growth

EBITDA / Margin

₹5,174 Mn / 14.4%



+32.2% YoY Growth

PAT¹ / Margin

₹2,365Mn / 6.6%



-22.7% YoY Growth

Exceptional items for the Q4 FY26 is ₹1350 Mn.²

Geographic-wise Break-Up

Domestic Business

₹23,245 Mn

+8.8% YoY Growth

International Business

₹12,223 Mn

+25.4% YoY Growth

Salient Numbers

230 bps

Outperformance in Acute vs. IPM

250 bps

Outperformance in Chronic vs. IPM

100 bps

Overall outperformance vs. IPM

1. PAT: Profit after Non-Controlling Interest; 2. Exceptional items for the quarter include an incremental ₹602.7 million towards the gratuity and leave encashment liability for past service cost following the finalisation of the Central Rules under the Labour Codes, and an impairment of ₹747 million for real estate investments.

FY26 Performance at Glance



Total Revenue from Operations

₹147,123 Mn

+13.5% YoY Growth

EBITDA / Margin

₹30,052 Mn / 20.4%

+19.6% YoY Growth

PAT¹ / Margin

₹23,018Mn / 15.6%

+6.3% YoY Growth

Exceptional items for the FY26 is ₹1748 Mn.²

Geographic-wise Break-Up

Domestic Business

₹98,514 Mn
+9.7% YoY Growth

International Business

₹46,810 Mn
+22.5% YoY Growth

Salient Numbers

₹54.74 Bn

Net Cash as of 31st Mar 2026

₹6,173 Mn

R&D spend for FY26

170 bps

Acute outperformance vs. IPM

4.2%

R&D spend as % of sales for the financial year

1. PAT: Profit after Non-Controlling Interest; 2. Exceptional items for the year include ₹1,130.6 million towards gratuity and leave encashment liability for past service cost following finalisation of Central Rules under the Labour Codes, and ₹747 million impairment of real estate investments, partly offset by a gain of ₹142.9 million on the sale of the Indore facility.

Q4 & FY26 – P&L Highlights



Particulars (All figures in ₹ Mn)	Q4FY26	Q4FY25	YoY growth	Q3FY26	QoQ growth	FY26	FY25	YoY growth
Revenue from Operations	36,033	31,438	14.6%	37,368	-3.6%	147,123	129,645	13.5%
Gross Profit	23,555	18,645	26.3%	24,641	-4.4%	96,195	82,003	17.3%
Gross Profit Margin	65.4%	59.3%		65.9%		65.4%	63.3%	
EBITDA	5,174	3,913	32.2%	8,280	-37.5%	30,052	25,122	19.6%
EBITDA Margin	14.4%	12.4%		22.2%		20.4%	19.4%	
PBT (before exceptional items)	5,578	3,963	40.7%	8,340	-33.1%	30,457	25,270	20.5%
Exceptional items¹	(1,350)	0		(528)		(1,748)	0	
PBT (after exceptional items)	4,229	3,963	6.7%	7,812	-45.9%	28,709	25,270	13.6%
PAT (after Non-Controlling interest)	2,365	3,059	-22.7%	6,360	-62.8%	23,018	21,655	6.3%
PAT Margin	6.6%	9.7%		17.0%		15.6%	16.7%	
EPS (₹/share)	19.8	25.6	-22.7%	53.2	-62.8%	192.5	181.1	6.3%

1: Exceptional items

For the quarter, exceptional items include an incremental ₹602.7 million towards the gratuity and leave encashment liability for past service cost following the finalisation of the Central Rules under the Labour Codes, and an impairment of ₹747 million for real estate investments.

For the year, include ₹1,130.6 million towards the same employee benefit liability, and ₹747 million impairment of real estate investments, partly offset by a gain of ₹142.9 million on the sale of the Indore facility.

CONTENTS



Company's Financial Performance



Business Updates – Q4 & FY26




Company overview and journey so far

Q4FY26 - Domestic Business Performance



**Q4 FY26 sales of ₹23,245 Mn
(8.8% YoY growth)**




- Domestic business¹ revenue grew by 8.8% YoY to ₹23,245 Mn from ₹21,355 Mn during the same period last year.
- Domestic revenue contributed 65.5% to total sales in Q4 FY26.
- According to IQVIA (SSA) data, for Q4 FY26:
 - The Company registered a growth of 11.1% YoY vs the Indian Pharmaceutical Market (IPM), which grew by 10.1%, 100 bps outperformance.
 - Acute segment reported growth of 10.0% vs IPM, which grew by 7.7%, 230 bps outperformance.
 - Chronic segment reported growth of 16.1% vs. IPM, which grew by 13.6%, 250 bps outperformance.
 - We have outperformed IPM in six therapies.

1. Includes revenue from Adroit and Alkem Medtech businesses.

Q4 FY26 - outpacing the market growth in six of the key focus therapies



Alkem growth vs. IPM growth



■ IPM Sales Growth YoY ■ Alkem Sales Growth YoY

Outperformance in 6 of the key IPM focus therapies

Therapy Class	Growth YoY %	Market share %	IPM Rank – Value
Anti Infectives	2.5% 2.4%	12.9% ↔	1 ↔
Gastro Intestinal	7.7% 13.8%	7.9% ↑+0.4%	4 ↔
VMN	12.5% 20.1%	6.4% ↑+0.4%	2 ↔
Pain / Analgesics	10.2% 17.0%	5.4% ↑+0.3%	3 ↔
Anti Diabetic	14.1% 20.1%	2.2% ↑+0.1%	14 ↑+1
Neuro / CNS	10.8% 6.7%	2.3% ↓-0.1%	8 ↔
Respiratory	8.2% 12.9%	1.5% ↑+0.1%	15 ↑+1
Derma	8.1% 16.5%	1.6% ↑+0.1%	18 ↑+1


15+ years of unmatched leadership in the Anti-Infectives therapy

Source: Market data as per IQVIA SSA Qtr. Mar'26

FY26 - Domestic Business Performance



**FY26 sales of ₹98,514 Mn
(9.7% YoY growth)**




- Domestic business¹ revenue grew by 9.7% YoY to ₹98,514 Mn from ₹89,837 Mn during the same period last year.
- Domestic revenue contributed 67.8% to total sales in FY26.
- According to IQVIA (SSA) data, for FY26:
 - The Company registered a growth of 9.2% YoY vs the Indian Pharmaceutical Market (IPM), which grew by 9.0%, 20 bps outperformance.
 - Acute segment reported growth of 8.5% vs IPM, which grew by 6.8%, 170 bps outperformance.
 - Chronic segment reported growth of 12.6% vs. IPM, which grew by 12.5%, 10 bps outperformance.
 - We have outperformed IPM in seven therapies.

1. Includes revenue from Adroit and Alkem Medtech businesses.

FY26 - outpacing the market growth in seven of the key focus therapies



Alkem growth vs. IPM growth



■ IPM Sales Growth YoY ■ Alkem Sales Growth YoY

Outperformance in 7 of the key IPM focus therapies


Therapy Class	Growth YoY %	Market share %	IPM Rank – Value
Anti Infectives	4.0% 4.4%	13.2% ↔	1 ↔
Gastro Intestinal	5.7% 8.3%	7.9% ↑+0.2%	4 ↔
VMN	9.2% 18.4%	6.7% ↑+0.5%	2 ↔
Pain / Analgesics	7.2% 11.6%	5.4% ↑+0.2%	3 ↔
Anti Diabetic	11.5% 14.2%	2.2% ↑+0.1%	15 ↔
Neuro / CNS	9.8% 8.6%	2.4% ↔	8 ↔
Respiratory	11.3% 16.2%	1.6% ↑+0.1%	15 ↔
Derma	6.1% 11.2%	1.5% ↑+0.1%	18 ↑+1

15+ years of unmatched leadership in the Anti-Infectives therapy

Source: Market data as per IQVIA SSA MAT Mar'26

Q4FY26 - US Business Performance

**Q4 FY26 sales of ₹7,681 Mn
(26.2% YoY growth)**




- US business¹ revenue grew by 26.2% YoY to ₹7,681 Mn from ₹6,086 Mn during the same period last year.
- The strong growth was mainly on account of continued growth traction in new launches and volume increase.
- US revenue contributed 21.7% to total sales in Q4 FY26.
- During the Q4 FY26, the Company filed 05 ANDAs, received 04 ANDAs approval (includes 2 tentative approvals).

1. Includes revenue from Enzene CDMO business.

US Market Filing and approvals status




ANDA / BLA Filings



As of March 31, 2026, the Company has **filed 192 ANDAs, 2 NDAs and 1 BLA** and has **received 167 ANDAs approvals** (including 19 tentative approvals) **and 2 NDAs approvals**.

FY26 - US Business Performance

**FY26 sales of ₹29,845 Mn
(20.3% YoY growth)**




- US business¹ revenue grew by 20.3% YoY to ₹29,845 Mn from ₹24,818 Mn YoY.
- The strong growth was mainly on account of continued growth traction in new launches and volume increase.
- US revenue contributed 20.5% to total sales in FY26.
- During FY26, the Company filed 08 ANDAs and 01 BLA, and received 17 ANDAs approval.

1. Includes revenue from Enzene CDMO business.

Q4FY26 - Non-US Business Performance


**Q4 FY26 sales of ₹4,543Mn
(24.1% YoY growth)**



- Non-US business revenue grew by 24.1% YoY to ₹4,543 Mn from ₹3,661 Mn during the same period last year.
- Non-US revenue contributed 12.8% to total sales in Q4 FY26.
- The Non-US business growth was driven by strong growth across all markets.

FY26 - Non-US Business Performance

**FY26 sales of ₹16,964Mn
(26.7% YoY growth)**




- Non-US business revenue grew by 26.7% YoY to ₹16,964 Mn from ₹13,392 Mn YoY.
- Non-US revenue contributed 11.7% to total sales in FY26.
- The Non-US business growth was driven by strong growth across all markets.

Facility Regulatory Status



Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Apr-26	Form 483 received; Audit response under submission
Taloja R&D (India)	Bioequivalence Centre	Apr-26	EIR Awaited - No observation received.
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Sep-25	EIR Awaited - No observation received

Shareholding Pattern as on Mar 31, 2026



■ Promoter & Promoter Group ■ Non-Institution
■ Institution

BSE Ticker	539523
NSE Symbol	ALKEM
Shares Outstanding (Mn)	120
MCap (Rs in Mn)*	633,495
Free Float MCap (Rs in Mn)	297,489
Industry	Pharmaceuticals

*Share Price - Rs 5,299 from NSE as of 31st Mar 26.

Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

Non-Institution – Public, Other Bodies Corporates, Clearing Members, Non-Resident Indians, Hindu Undivided Family and Trusts

CONTENTS



Company's Financial Performance



Business Updates – Q4 & FY26



Company overview and journey so far

Alkem Laboratories at Glance (FY26)



#3
Rank in
Prescriptions¹

#6
Rank by value in
IPM²

Leading Player
In the Trade
Generics segment

Top 4
Player in 4 out of top
7 largest IPM's TAs²



₹1,47,122 Mn
Total Revenue³

67.8%
Domestic Revenue

20
Brand families worth
₹1000 Mn+²

13,500+
Field force⁴



65.4%
Gross Profit
Margin

20.4%
EBITDA Margin

15.6%
PAT Margin

29.4%
ROCE (Pre-Tax)

1. Prescriptions data as per SMSRC MAT Feb'26; 2. Market data as per IQVIA SSA MAT Mar'26; 3. Including Other Operating Income; 4. Excluding Line Managers as of 31st March 2026

Strong momentum from our mega brands has been pivotal in building robust brand franchises and consistently scaling them over the years



#2 'PAN'

Biggest Brand family in the IPM

15 Brands

in the IPM Top 300 ranks

37 Brands

Among the Top 3 ranks in their CVM¹ (Brands > ₹250 Mn)


Building large brand families defines our identity...


Brand Families	MAT Mar'21	MAT Mar'26	CAGR (5 Yrs.)
> ₹10 Bn	0	1	15.2%
> ₹5 Bn	1	1	12.4%
> ₹1.5 Bn	5	12	12.4%
> ₹500 Mn	15	16	11.2%


Brand family > ₹5 Bn


PAN CLAVAM

Brand family > ₹1.5 Bn





























Source: Market data as per IQVIA SSA MAT Mar'26; 1. CVM is Covered Market

50+ years of Alkem journey – a snapshot



Alkem & key subsidiaries

Source: Internal data

THANK YOU

For any queries, contact:
Purvi Shah – Head of Investor Relations
Mobile: +91 84337 00890
E-mail: purvi.shah@alkem.com
Tel: +91 22 3982 9999 Ext: 9447

Stay updated on     

Disclaimer: This is a confidential email from Alkem Laboratories Limited. The contents of this email and any attachments are solely intended for the addressee(s) and in all likelihood contain information that is legally privileged. If you are not the intended recipient of this email, you are on notice of its status and we request you to kindly advise us by return email immediately. Please also simultaneously disregard the contents herein, delete this email from your computer and server and also destroy any physical copies, if created. You are hereby notified that any use, any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this e-mail, its contents or its attachment/s other than by its intended recipient/s is strictly prohibited and may be construed unlawful. Alkem Laboratories Limited does not accept any liability for the views expressed in this email or for the consequences of any viruses that may be transmitted with this email. The content of this email is subject to copyright and no part hereof may be reproduced, adapted or transmitted without the written consent of Alkem Laboratories Limited.

 Conserve to Preserve. Think before you Print.